Business
Herantis Pharma releases 1H 2025 report today
Espoo, Finland, 21 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, releases today the Company’s 1H 2025 report. The full report is available at the Company’s website: www.herantis.com. Antti Vuolanto, CEO of Herantis, said: “We made significant clinical progress in the first half of 2025, advancing HER-096 through the Phase 1b study which is now approaching completion on schedule, a key milestone. We repo
About this update from Herantis Pharma Plc
[{"type":"image","alt":"Herantis Pharma plc","displaySize":"","headline":null,"caption":"Herantis Pharma plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TztkX3djp9fmQ02UkZu7vQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646","width":300,"height":51}},"lazy":false},{"type":"text","content":"Espoo, Finland, 21 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, releases today the Company’s 1H 2025 report. The full report is available at the Company’s website: www.herantis.com.","length":291,"tagName":"p"},{"type":"text","content":"Antti Vuolanto, CEO of Herantis, said: “We made significant clinical progress in the first half of 2025, advancing HER-096 through the Phase 1b study which is now approaching completion on schedule, a key milestone. We reported encouraging pharmacokinetic data from Part 1 of the study in healthy volunteers and completed the final patient visit in Part 2, which is evaluating HER-096 in individuals with Parkinson’s disease. The upcoming topline data readout, expected by mid-October, will be an important inflection point for Herantis. While we are preparing for the Phase 2 study, the final design will be guided by the full Phase 1b dataset, which we anticipate will be available later this year. HER-096 has the potential to become the first disease-modifying treatment for Parkinson’s disease, and we remain committed to bringing this transformative therapy to patients living with this devastating condition.”","length":916,"tagName":"p"},{"type":"text","content":"Herantis will hold a webcast related to the 1H report today, Thursday, 21 August at 10:00 EEST (9:00 CEST)","length":106,"tagName":"p"},{"type":"text","content":"Please use the following link to register for the webcast: https://herantis.videosync.fi/q2-2025.","length":102,"tagName":"p"},{"type":"text","content":"Questions can be submitted throughout the webcast event. A recording of the webinar will be made available on the Company’s website.","length":132,"tagName":"p"},{"type":"text","content":"Business highli...